Lund, S.E., August 15, 2024 – TFS HealthScience (TFS), a leading global Contract Research Organization (CRO), announces the appointment of Victoria Hornagold as the new Vice President of Clinical Development Services (CDS). Based in Norfolk, United Kingdom, Hornagold will play a pivotal role in enhancing TFS’s commitment to delivering superior services and improving patient outcomes globally.
Hornagold brings over 25 years of clinical research experience, having held senior management positions at prominent CROs, including Cmed Clinical Services and Aixial Group. Most recently, she served as Head of Project Management at Aixial Group, where she was instrumental in driving process efficiencies and ensuring high-quality outcomes for customers.
In her new role, Hornagold will oversee TFS’s clinical development services, including biometrics, contract management, drug safety and pharmacovigilance, medical and site monitoring, medical writing, quality, study start-up, and trial master file delivery. Her leadership will focus on enhancing client delivery through innovative, patient-centric practices and streamlined processes. With her guidance, TFS expects to deliver faster, more reliable business processes and organizational practices, resulting in enhanced project outcomes and upholding the highest standards of compliance and quality.
“Victoria’s extensive experience and strategic approach to clinical development services will be invaluable as we continue to grow and enhance our services for our customers,” said Bassem Saleh, CEO of TFS. “Her commitment to operational excellence and collaborative leadership aligns perfectly with our goals and mission. As a welcome addition to our executive management team, she brings new energy and insight that will further our success. We are excited to welcome her to our team and look forward to the positive impact she will have on our customers’ success and patient care.”
“Having spoken with TFS employees from diverse teams over the last months, I have been impressed by the openness, commitment, and positivity,” expressed Hornagold. “TFS has a clear identity and vision for the future, and I am very proud to be joining this dynamic team.”
Hornagold’s appointment is set to significantly benefit TFS’s customers and partners by enhancing service quality and collaboration and create a more efficient and motivated workforce by fostering innovation and continuous improvement. Hornagold’s addition to the team further underscores TFS’s ongoing dedication to operational excellence and patient-centric innovation, benefiting customers, patients, and employees alike.
About TFS HealthScience
TFS HealthScience is a full-service, global Contract Research Organization (CRO) that supports biotechnology and pharmaceutical companies throughout their entire clinical development journey. In partnership with customers, we build solution-driven teams working towards a healthier future. Bringing together nearly 800+ professionals, TFS delivers tailored clinical research services in more than 40 countries with flexible clinical development and strategic resourcing solutions across key therapeutic areas, including Dermatology, Immunology & Inflammatory Diseases, Internal Medicine, Neuroscience, Oncology & Hematology, and Ophthalmology.
Detailed information about TFS and its business offerings can be obtained through www.tfscro.com.